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Polymorphisms of the glucose transporter (GLUT1) gene are It affects approximately one third of patients with type 1
associated with diabetic nephropathy. diabetes, and the incidence peaks between 15 and 20
Background. Diabetic nephropathy (DN) is a major cause years duration of diabetes [2]. These observations, to-of morbidity and mortality in patients with type 1 diabetes
gether with those showing familial aggregation of ne-mellitus. Recent studies suggest that genetic factors, including
phropathy, suggest that genetic factors play an importantpolymorphisms in the flanking region of the aldose reductase
gene (59ALR2), play an important role in the pathogenesis of role in determining the susceptibility to DN [3–5].
nephropathy. Glucose transporter (GLUT1) activity has been Recent studies have shown that polymorphisms in the
implicated in renal hypertrophy and extracellular matrix forma- gene coding for aldose reductase (ALR2), the first andtion in mesangial cells. The aim was to investigate the frequency
rate-limiting enzyme of the polyol pathway, are associ-of a polymorphism within the GLUT1 gene in 186 Caucasoid
ated with susceptibility to DN in patients with type 1patients with type 1 diabetes and 104 normal controls.
Methods. Amplimers flanking the Xba-I polymorphic site diabetes [6, 7]. Preferential transmission of the Z-2 59
in the second intron were employed to amplify DNA from ALR2 susceptibility allele also has been demonstrated
subjects. The amplified DNA was restricted with endonuclease
from parent to affected proband with nephropathy andXba-I, separated by gel electrophoresis, and visualized. In the
type 1 diabetes [8]. Sib-pair analysis has also shown link-absence of an Xba-I site, a fragment of 1.1 kilobase was seen,
whereas fragments of 0.9 and 0.2 were generated if the Xba-I age with nephropathy in Pima Indians with type 2 diabe-
site was present. tes and chromosome 7q35, the region where ALR2 is
Results. There was a highly significant increase in the fre- located. However, these associations with the ALR2
quency of the 1.1 allele in those patients with nephropathy
gene cannot account for all of the genetic susceptibility(N 5 70) compared with those with no proteinuria or retinopa-
to DN. For instance, there are individuals with the Z-2thy after 20 years of diabetes (uncomplicated N 5 44, 61.4 vs.
40.9%, respectively, P , 0.001). The 1.1/1.1 genotype was also 59ALR2 susceptibility allele who have remained free
significantly increased in the nephropathy group compared of any microvascular complication after many years of
with the uncomplicated group of patients (37.1 vs. 13.6%, re- diabetes. Conversely, there are those patients with thespectively, P , 0.01). The frequency of the 1.1/1.1 genotype
Z12 “protective” allele who have readily developed ne-was similar in 30 patients with retinopathy but not nephropathy
phropathy. This supports a role for other genetic factors.when compared with the uncomplicated group of patients (13.6
vs. 16.7%). Furthermore, only 8 out of 49 patients with DN It is plausible that the uptake and availability of glu-
had the Z12 59ALR2 DN “protective” allele and the 0.9 cose into the kidney may have important implications
GLUT1 allele in contrast to 21 out of 39 uncomplicated patients for the flux through the polyol pathway. For instance,(P , 0.0002).
whereas the Z-2 allele has been shown to be associatedConclusion. These results suggest that the GLUT1 gene to-
with increased mRNA in patients with nephropathy [7],gether with the aldose reductase gene are associated with sus-
ceptibility to DN in patients with type 1 diabetes. unless glucose was readily available, this would not lead
to any major increase in flux through the polyol pathway.
The glucose transporters mediate the facilitative up-
Diabetic nephropathy (DN) is a major cause of mor- take of glucose into cells. Within the glomeruli of the
bidity and mortality in patients with type 1 diabetes [1]. kidney, the glucose transporter 1 (GLUT1) is known to
be the most important facilitative glucose transporter
[9, 10]. Previous studies investigating the role of GLUT1Key words: aldose reductase gene, diabetes mellitus, heredity, ALR2,
polymorphism of GLUT1. as a candidate gene for nephropathy in type 2 diabetes
have been conflicting, and there have been no reportsReceived for publication June 14, 2000
in patients with type 1 diabetes [11, 12]. The aim of ourand in revised form September 11, 2000
Accepted for publication September 28, 2000 study was to investigate a polymorphism of GLUT1 gene
in a large population of Caucasoid patients with type 1Ó 2001 by the International Society of Nephrology
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Table 1. Clinical characteristics of patients with type 1 diabetes mellitus and normal healthy controls
Uncomplicated Nephropaths Retinopaths Short duration Normal controls
N 5 44 N 5 70 N 5 30 N 5 42 N 5 104
Male:female 22:22 30:40 19:11 20:22 63:41
Age at onset of diabetes years 16.6 (1–42) 16.4 (1–33) 20.5 (1–37) 10.6 (1–46) —
Duration of diabetes years 30.8 (20–54) 31.4 (10–51) 29.4 (13–47) 9.9 (4–17)
The results are shown as mean and range (in parentheses) in years.
Uncomplicated patients have had type 1 diabetes for at least 20 years but remain free of retinopathy and proteinuria. Nephropaths have had type 1 diabetes for
a 10 year duration and have proteinuria (3 positive Albustix over the past 12 months) and retinopathy. Retinopaths have more than five dots or blots per eye, hard
or soft exudates new vessels or fluorescein angiographic evidence of maculopathy or previous laser treatment for pre-proliferative or proliferative retinopathy, and
maculopathy or vitreous hemorrhage. None of these patients had proteinuria. The short duration patients have had type 1 diabetes for less than 20 years but do not
have any microvascular complications.
diabetes and nephropathy who had previously been (Scotlab, Paisley, Scotland, UK). An aliquot of this
DNA was amplified using the polymerase chain reactiontyped for 59ALR2 polymorphisms.
(PCR). A pair of amplimers was designed to amplify
specifically the GLUT 1 gene. The amplification reaction
METHODS
was performed in 30 mL volumes, containing the ampli-
Patients and normal control subjects mers 59 TGT GCA ACC CAT GAG CTA A 39 and 59
CCT GGT CTC ATC TGG ATT CT 39, 10 mmol/LDNA samples from 186 British Caucasoid patients
with type 1 diabetes were randomly taken from the dNTPs (Pharmacia Biotech, Uppsala, Sweden), 10 3
buffer solution, 25 mmol/L MgCl2, and 1 U Taq polymer-freezer for analysis. A total of 104 DNA samples from
normal healthy British Caucasoid subjects was randomly ase (HT Biotech, Cambridge, UK). The samples were
subjected to 30 cycles of amplification in a three-steptaken from the freezer to obtain control frequencies.
reaction that consisted of denaturation for 1 minute andThe normal controls consisted of DNA from cord blood
30 seconds at 948C, annealing for 1 minute and 30 secondssamples collected sequentially after normal obstetric de-
at 508C, and extension for 1 minute 30 seconds at 728Clivery from the Obstetric Department, Derriford Hospi-
in either a PTC-200 Thermal Cycler (MJ Research, Es-tal (Plymouth, UK). Local ethical committee approval
sex, UK) or an i Cycler Thermal Cycler (Biorad, Hemelhad been obtained. The patients were classified ac-
Hempstead, UK). Amplification resulted in a 1.1 kbcording to their microvascular complications as pre-
DNA fragment that included the Xba-I polymorphic site.viously described [6]. These are summarized as follows:
Uncomplicated patients. These patients (N 5 44) had
Identification of the Xba-I polymorphism in thetype 1 diabetes for at least 20 years but remained free
GLUT1 geneof retinopathy (fewer than five dots or blots per fundus)
and proteinuria (urine Albustix negative on three con- The Xba-I polymorphic site is located in the second
intron of the gene. The polymorphism consists of a gua-secutive occasions over 12 months).
Nephropaths. These patients (N 5 70) had type 1 dia- nine (G) being transversed to a thymine (T), which re-
sults in the recognition site being abolished. The PCRbetes for a duration of 10 years, and had proteinuria (3
positive Albustix over the past 12 months) and retinop- products were digested with 10 units of the Xba-I restric-
tion enzyme (Promega, Southampton, UK) for one toathy.
Retinopaths. These patients (N 5 30) had retinopathy two hours at 378C. The resulting digested fragments were
separated by gel electrophoresis on a 1.5% agarose geldefined as more than five dots or blots per eye, hard or
soft exudates, new vessels, or fluorescein angiographic (Roche Diagnostics, Mannheim, Germany) and visual-
ized under ultraviolet light and scored. If the Xba-I siteevidence of maculopathy or previous laser treatment for
preproliferative or proliferative retinopathy, and macu- is present, two fragments of 0.2 and 0.9 kb were gener-
ated; if the Xba-I site is not present, a fragment of 1.1 kblopathy or vitreous hemorrhage. None of these patients
had proteinuria. Fundoscopy was performed by both a in size was generated.
diabetologist and ophthalmologist.
Statistical analysisShort duration. These patients (N 5 42) had a dura-
tion of diabetes of less than 20 years but had no evidence The frequency of alleles and genotypes in the patient
of retinopathy, proteinuria, or overt neuropathy. subgroups and normal controls was compared using the
The clinical features of the patients are shown in Table 1. x2 test and contingency tables. The P values were cor-
rected for the number of comparisons made (Pc) using
Preparation of DNA and amplification of the GLUT1 gene the Bonferroni inequality method [13], and Pc values of
,0.05 were considered to be significant. Where appro-High molecular weight DNA was prepared from
10 mL of peripheral blood using Nucleon extraction kits priate, the odds ratio was calculated.
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Table 2. Frequency of GLUT1 Xba-I alleles and genotypes in patients with type 1 diabetes mellitus and normal healthy controls
Uncomplicated Nephropaths Retinopaths Short duration Normal controls
N 5 44 N 5 70 N 5 30 N 5 42 N 5 104
Genotype
1.1/0.9 54.5 (24) 48.6 (34) 63.3 (19) 69.0 (29) 57.7 (60)
1.1/1.1 13.6b (6) 37.1a (26) 16.7b (5) 23.9 (10) 22.1 (23)
0.9/0.9 31.8 (14) 14.3 (10) 20.0 (6) 7.1 (3) 20.2 (21)
Allele
1.1 40.9 (36) 61.4c,d (86) 48.3 (29) 58.3 (49) 51.0 (106)
0.9 59.1 (52) 38.4 (54) 51.7 (31) 41.7 (35) 49.0 (102)
The number of subjects is given in parentheses.
a P , 0.01 vs. uncomplicated; x2 5 7.1
b P , 0.0025 vs. nephropaths; x2 5 9.4
c P , 0.0025 vs. uncomplicated; x2 5 9.2
d P , 0.003 vs. non-nephropaths; x2 5 8.8
RESULTS frequency of the 0.9/0.9 genotype in the nephropaths
(14.3 vs. 31.8%). The retinopaths did not differ from theThe mean duration of diabetes in the uncomplicated,
uncomplicated group or the normal controls. Althoughnephropaths, and retinopaths was similar (30.8, 31.4, and
the frequency of the 1.1/1.1 genotype was different be-29.4 years, respectively). It is unlikely that many of the
tween the nephropaths and retinopaths, this did notpatients in the retinopathy group would now develop
reach significance after correction of the P value (x2 5nephropathy.
4.3, P , 0.05, Pc 5 NS). The difference in the genotypeDigestion of the amplification products with the re-
frequencies was also reflected in the allelic frequenciesstriction endonuclease Xba-I yielded fragments of either
(Table 2). The nephropaths had a significant increase in1.1 kb or 0.9 and 0.2 kb in the presence of the polymor-
the frequency of the 1.1 allele compared with the uncom-phic Xba-I restriction site, and these generated GLUT1
plicated group (61.4 vs. 40.9%, x2 5 9.2, P , 0.0025) asgenotypes of 1.1 0.9/0.2 1.1 or 0.9/0.2, as previously de-
well as the non-nephropaths (x2 5 8.8, P , 0.003). Thescribed [11]. For simplicity, these alleles are designated
frequency of the GLUT1 alleles was similar between the1.1 or 0.9. Table 2 shows the frequency of the GLUT1
normal controls, retinopaths, and those patients withgenotypes and alleles in the patient subgroups and
short duration of diabetes (51.0 vs. 48.3 and 58.3%, re-normal controls. In the normal control population,
spectively). There were no differences in the frequencythe GLUT1/Xba-I genotypes were in Hardy–Weinberg
of the GLUT1 alleles and genotypes with gender be-equilibrium (x2 5 2.6). However, the normal controls
tween the patients subgroups or the normal controls.were different from those reported in nondiabetic Chi-
Forty-nine of the nephropaths and 39 of the uncompli-nese subjects. In our British Caucasoid population, there
cated subjects had been genotyped for the 59ALR2 poly-was an increased frequency of the GLUT1 1.1 allele
morphism in the 59 flanking region of the ALR2 gene.compared with the Chinese population (51.0 vs. 21.0%).
The GLUT1 together with the 59ALR2 genotypes wereInterestingly, the genotypes reported for the Chinese
analyzed together to determine whether any preferentialpopulation also conform to Hardy–Weinberg equilib-
combination of markers occurred. The results are shownrium, suggesting that these differences may be due to
in Table 3. In the nephropaths, 10 of the 49 subjects hadethnicity. A comparison of the GLUT1 genotype fre-
a GLUT1 1.1/1.1 genotype together with the Z-2/X orquencies in all patients (N 5 186) compared with the
Z-2/Z 2 59ALR2 genotype compared with none of thenormal controls showed them to be nearly identical.
39 uncomplicated patients (20.4 vs. 0.0%, x2 5 9.0, P ,However, when the 186 patients were subgrouped ac-
0.002, Pc 5 0.022, odds ratio 5 9.5). Furthermore, thecording to the presence or absence of microvascular com-
“protective” combination of the GLUT1 0.9/0.9 orplications, there were marked differences in the fre-
0.9/1.1 genotype with the Z12/X or Z12/Z-2 59ALR2quency of the GLUT1 genotypes and alleles. In the
genotype was present in only 8 out of 49 nephropathspatient population, there was a significant increase in
compared with 21 out of 39 uncomplicated subjects (16.3the frequency of the GLUT1 1.1/1.1 genotype in the
vs. 53.8%, x2 5 13.8, P , 0.0002, Pc 5 0.0022). Thisnephropaths compared with the uncomplicated group
combination was found in 25% of the short duration(37.1 vs. 13.6%, x2 5 7.1, P , 0.01, Pc 5 0.02). This
patients. The “protective” combination of GLUT1 0.9difference remained significant when the nephropaths
and the Z12 59ALR2 alleles was found in 23 out of 39were compared with the uncomplicated together with
of the uncomplicated patients compared with 8 out ofthe retinopaths (non-nephropaths; x2 5 7.1, P , 0.01,
49 of the nephropaths (59.0 vs. 16.3%, x2 5 17.4, P ,Pc 5 0.02).
This increase was accompanied by a decrease in the 0.00001, Pc 5 0.0001). There were no significant differ-
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Table 3. Frequency of GLUT1 and 59ALR2 genotypes in patients there may be subtle interactions between the flux
with type 1 diabetes mellitus and diabetic nephropathy
through the polyol pathway and function of the GLUT1
Uncomplicated Nephropaths Normal controls and glucose transport into the cell.
GLUT1; 59ALR2 N 5 39 N 5 49 N 5 56 Recent studies in rodents using cultured glomerular
1.1/0.9; Z22/X 15.4 (6) 12.2 (6) 26.8 (15) cells have demonstrated that GLUT1 is the predominant
1.1; Z22/X 0.0 (0) 18.4 (9)b 0.0 (0)
facilitative glucose transporter [9, 10, 14]. It has also0.9; Z22/X 7.7 (3) 12.2 (6) 3.6 (2)
been shown that overexpression of the human GLUT11.1/0.9; Z12/X 30.8 (12)a 8.2 (4)c 16.1 (9)
gene in cultured rat mesangial cells can mimic the effects1.1; Z12/X 5.1 (2) 0.0 (0) 7.1 (4)
0.9; Z12/X 15.4 (6)a 2.0 (1)c 1.8 (1) of the diabetic milieu [15]. Consequently, it is possible
1.1/0.9; Z22/Z12 5.1 (2)a 6.1 (3)c 5.3 (3) that the 1.1 kb allele that we and others have found to
1.1; Z22/Z12 0.0 (0) 2.0 (1)b 1.8 (1) be increased in patients with nephropathy has a different0.9; Z22/Z12 2.6 (1)a 0.0 (0)c 1.8 (1)
rate of glucose transport than the 0.9 kb allele. The
1.1/0.9; X/X 5.1 (2) 24.5 (12) 14.3 (8)
increased transport of glucose would exacerbate the flux1.1; X/X 2.6 (1) 8.2 (4) 12.5 (7)
0.9; X/X1 10.2 (4) 6.1 (3) 8.9 (5) through the polyol pathway. We already know that the
The number of subjects is given in parentheses. X 5 any 59ALR2 allele other 59ALR2 Z-2 allele is associated with nephropathy and
than Z22 or Z12. increased mRNA levels. Therefore, those individualsa P , 0.0002 vs. nephropaths, x2 5 13.8
b P , 0.002 vs. uncomplicated, x2 5 9.0, with both the 1.1 kb GLUT1 allele as well as the Z-2
c P , 0.00001 vs. uncomplicated, x2 5 17.4 allele would be at a much higher risk of developing
nephropathy than those without. The results presented
here suggest that individuals with this combination have
an odds ratio of 9.5 of having nephropathy. Conversely,ences in the frequency of the combination of the “suscep-
those patients with the 0.9 kb allele and a neutral ortibility” alleles between these groups of patients. The
protective 59ALR2 allele would have a very low risk offrequency of the GLUT1 1.1 allele without the Z-2
developing nephropathy.59ALR2 was not significantly different between the
It is interesting that the Z-2 59ALR2 allele is associatednephropaths and the uncomplicated group. Similarly, the
with retinopathy in both types 1 and 2 diabetes as wellfrequency of the Z-2 59ALR2 allele without the GLUT1
as in different ethnic backgrounds. However, we have1.1 allele was not significantly different between these
found no evidence for a role for GLUT1 in the suscepti-groups. Fifteen of the 21 nephropaths with the Z-2/X
genotype had at least one copy of the GLUT1 1.1 allele. bility to retinopathy, and our results support those re-
The number of subjects in the retinopaths was too small ported for Chinese patients with type 2 diabetes and
to be analyzed. retinopathy. Given the important role of GLUT1 in the
mesangial cells of the kidney, this is not surprising. It
also suggests that the influence of the polyol pathwayDISCUSSION
on the pathogenesis of DN compared with retinopathy
In this study, we confirmed the previous report of an probably involves different mechanisms at the molecular
association between a polymorphism in the second in- and cellular level.
tron of the GLUT1 gene and susceptibility to DN. In In conclusion, our results show that the GLUT1 gene
contrast to the previous report [11], this population con- is intricately involved in the susceptibility to nephropathy
sists of British Caucasoid patients with type 1 diabetes. but not retinopathy in Caucasoid patients with type 1
Both studies found an association between the GLUT1 diabetes. Furthermore, there appears to be an interac-
1.1 kb allele and DN, although we found the homozygous tion between the ALR2 and GLUT1 genes that could
1.1 genotype to be over-represented, whereas in the Chi- help to explain why some patients with well-controlled
nese population, it was the heterozygous 1.1/0.9 geno- diabetes still develop nephropathy, whereas there are
type. The frequency of the GLUT1 1.1 allele is signifi-
others with poorly controlled diabetes who “escape”
cantly lower in the Chinese compared with the British
from this complication.Caucasoid population of normal controls. The differ-
ences in allelic frequency will explain the differences in
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